Stevens Capital Management LP acquired a new stake in Impax Laboratories, Inc. (NASDAQ:IPXL) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 9,984 shares of the specialty pharmaceutical company’s stock, valued at approximately $203,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Public Employees Retirement System of Ohio raised its holdings in Impax Laboratories by 12.7% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 6,911 shares of the specialty pharmaceutical company’s stock valued at $111,000 after acquiring an additional 780 shares in the last quarter. Advisory Services Network LLC acquired a new position in Impax Laboratories in the 2nd quarter valued at $207,000. Virtu KCG Holdings LLC acquired a new position in Impax Laboratories in the 2nd quarter valued at $231,000. State of Alaska Department of Revenue raised its holdings in Impax Laboratories by 78.7% in the 2nd quarter. State of Alaska Department of Revenue now owns 14,548 shares of the specialty pharmaceutical company’s stock valued at $234,000 after acquiring an additional 6,408 shares in the last quarter. Finally, Piedmont Investment Advisors LLC acquired a new position in Impax Laboratories in the 2nd quarter valued at $257,000. 86.09% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Stevens Capital Management LP Takes Position in Impax Laboratories, Inc. (IPXL)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/22/stevens-capital-management-lp-takes-position-in-impax-laboratories-inc-ipxl.html.

Several brokerages have recently issued reports on IPXL. BidaskClub lowered Impax Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Canaccord Genuity set a $19.00 price target on Impax Laboratories and gave the company a “hold” rating in a research note on Wednesday, August 9th. Cowen and Company set a $20.00 price target on Impax Laboratories and gave the company a “hold” rating in a research note on Wednesday, August 9th. Piper Jaffray Companies set a $17.00 price target on Impax Laboratories and gave the company a “hold” rating in a research note on Thursday, August 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price target (up previously from $20.00) on shares of Impax Laboratories in a research note on Wednesday, September 6th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $19.60.

Shares of Impax Laboratories, Inc. (IPXL) opened at $16.85 on Wednesday. The firm has a market capitalization of $1,219.17, a price-to-earnings ratio of 24.19, a P/E/G ratio of 1.04 and a beta of 0.99. Impax Laboratories, Inc. has a 52-week low of $7.75 and a 52-week high of $25.70. The company has a current ratio of 1.81, a quick ratio of 1.32 and a debt-to-equity ratio of 1.59.

Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.03. The business had revenue of $206.40 million for the quarter, compared to analyst estimates of $208.38 million. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. Impax Laboratories’s quarterly revenue was down 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.37 EPS. analysts forecast that Impax Laboratories, Inc. will post 0.63 earnings per share for the current fiscal year.

Impax Laboratories Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Want to see what other hedge funds are holding IPXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Impax Laboratories, Inc. (NASDAQ:IPXL).

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Stock Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related stocks with our FREE daily email newsletter.